Because of the rapidly increasing incidence of serious candidal infections, a consensus conference of 22 investigators from the United States, Europe, and Japan was held to discuss strategies for the prevention and treatment of deep-organ infections caused by Candida species. Commonly asked questions concerning the management of candidal infections were selected for discussion by the participating investigators. Possible answers to the questions were developed by the investigators, who then voted anonymously for their preferences. In certain instances, unanimity or a strong consensus was the result. In all cases, the full spectrum of responses was recorded and is presented in this report. The forms of candidal infection addressed included candidemia, candiduria, hepatosplenic candidiasis (chronic systemic candidiasis), candidal endophthalmitis, and candidal peritonitis. Prevention and treatment strategies were considered for patients who have undergone surgery, for neutropenic and nonneutropenic patients, and for patients who have undergone bone marrow and solid organ transplantation. The therapeutic roles of amphotericin B (standard and lipid formulations) and the azoles were considered.
According to the results of the National Nosocomial Infecbeen described [5] . DNA typing has verified that transmission occurs from patient to patient and from health care worker tions Surveillance System surveys conducted through 1992, Candida has become the fourth most common isolate recovered to patient. Numerous risk factors for candidemia have been identified. They vary among institutions but usually include use from blood cultures in the United States [1] , and rates of candidemia have increased substantially in Europe as well [2] . Epiof antibiotics, indwelling catheters, hyperalimentation, cancer therapy, and immunosuppressive therapy after organ transdemiological studies have shown that candidal infections occur on both medical and surgical services; approximately half of plantation; hospitalization in intensive care units; candiduria; and colonization with Candida species. all candidal infections occur in surgical intensive care units. A noticeable shift in the species of Candida causing infection toward non-albicans species has occurred (table 1) [3 -5] . NuSee editorial response by Graybill on pages 60 -2. merous instances of nosocomial transmission of Candida species, which have led to outbreaks or clusters of cases, have
Although the incidence of serious infections due to Candida species is rising rapidly, knowledge of the most appropriate strategies for the management of such infections remains se- was given to each investigator before the meeting. During the meeting, the questions were projected onto a screen of suffi-* Data are from [30] .
cient size to allow all investigators to view the document simultaneously. The questions were extensively reviewed and edited, and new questions were discussed and added. Finally, the wordThe problems of studying serious candidal infection are foring of possible answers to the questions was reviewed, extenmidable because of the complex disease profiles of the patients.
sively discussed, and revised. The purpose of this conference of investigators with extensive
After the final versions of the questions and possible answers experience in treating candidal diseases was to develop a conhad been formulated, the issues were discussed and the answers sensus, when possible, on the most effective strategies for the to the questions were voted on with use of electronic devices prevention and clinical management of severe candidal infecat the participants' seats. To eliminate the influence of peers tions. When a consensus could not be reached, the goal was
[6], voting was anonymous, and the outcome was not known to report the full diversity of opinion. Because so few doseby the conference participants until the voting was completed. ranging studies have been performed in patients with severe Each time a vote was taken, all investigators present voted candidal infections, in many instances dosing recommendations (abstention was not permitted). Because some investigators could not be given. The results of studies now in progress were unable to be present for each vote, the number of votes should allow more precise dosing recommendations in the did not always total 22. Drafts in progress and final copies of future.
the manuscript were distributed to all participants for their approvals before submission for publication. 
Methods

Terminology
Management of Candidemia in Nonneutropenic Patients and General Concepts of the Management of Candidemia
Should all candidemic patients (either neutropenic or nonneutropenic) be treated with an antifungal? remain severely limited. A 24-center study in which fluconaBackground data. The mortality rates associated with candizole was compared with amphotericin B has been completed demia are high, ranging from Ç40% to 60% [1] . Retrospective in the United States [4] . In this study, nonneutropenic patients studies have shown an error rate of Ç30% in defining a populawho did not have leukemia, lymphoma, or AIDS and had not tion of candidemic patients who do not require treatment [7, 8] .
undergone organ transplantation were treated with either amAs with nearly all infections, there are certain patients who photericin B or fluconazole for an additional 2 weeks after the survive candidemia without receiving specific antibiotic treatlast positive blood-culture results were obtained. There was no ment. At present, however, there are no accurate diagnostic tests statistical difference in clinical response between the two to define a population of patients with candidemia who do not agents. A smaller study showed similar results [9] . require antifungal treatment. In addition, current methods of risk
Responses. The agents chosen by the investigators for the factor analysis are not accurate enough to assign a probability management of candidemia in stable and unstable nonneutroof deep-organ infection to a population of candidemic patients.
penic patients are summarized in tables 2 and 3, respectively.
Responses. Nineteen of 20 investigators answered this
For patients whose Candida isolates were not resistant to flucoquestion in the affirmative (figure 1). This strong consensus is nazole and who had no evidence of hematogenous seeding, 20 based on three pivotal facts: (1) predicting which patients need of 20 investigators chose fluconazole. If the patient had received treatment is associated with an unacceptable level of inaccuprevious treatment with fluconazole, even if the patient was racy; (2) fluconazole for the treatment of candidemia has been published [10] . In addition, there are no clear-cut dose-response data Background data. The data available to guide the choice of antifungal agents for treatment of nonneutropenic patients available for amphotericin B. 
Should indwelling intravenous catheters be changed
Responses. implanted line. The results of a number of studies suggest investigators indicated that they aim for peak serum levels of that catheter exchanges may be associated with more rapid 51 -100 mg/mL if serum levels are readily obtainable. Only clearance of the bloodstream and perhaps a better outcome one investigator aims for a level of ú100 mg/mL, and three [4, 7, 8, 11, 12] . Although the value of each of these studies of 20 aim for levels of õ50 mg/mL. All investigators agreed is limited by at least some potential bias and none of the that the dose should be adjusted for patients with renal insuffistudies accounts for the potential role of the gastrointestinal ciency. Serum levels of 20 -75 mg/mL are well above the MIC of 5-fluorocytosine for most Candida isolates.
tract in the pathogenesis of candidemia, the collective data strongly suggest that consideration should be given to the antifungal therapy should be considered for critically ill, nonneutropenic patients (who have multiple risk factors for dissemremoval or changing of all intravascular catheters, especially in patients with persistent candidemia.
inated candidiasis) with signs of infection who have not responded to optimal antibacterial therapy and have had thorough evaluations for bacterial infection.
What is the role of prophylactic antifungal agents in
Responses. When Candida species are isolated from specinonneutropenic patients?
mens such as sputum or urine from a nonneutropenic patient The investigators were unanimous in their belief that antifunwith two or more risk factors for invasive candidiasis, 18 of gal prophylaxis should not be given on a routine basis and that 20 investigators indicated they would administer empirical it should be reserved for selected nonneutropenic patients at therapy. When no Candida species are isolated, only 10 of 20 high risk for candidemia. An example of a situation that might investigators would administer empirical therapy. The question warrant prophylaxis is that in which a patient has received of whether routine surveillance cultures should be performed antibacterial therapy for ú14 days, has indwelling intravascular for such patients was not addressed. lines in place, is receiving hyperalimentation fluids, has had Candida isolated from two or more sites, and has undergone When the decision is made to use empirical therapy, 
receiving systemic antifungal prophylaxis)?
Background data. Both antifungal prophylaxis and empiriWhen should empirical therapy be given to cal therapy are costly, and the benefit of an agent must be nonneutropenic patients?
weighed against its costs. The potential for selecting for strains resistant to azoles is an additional reason to administer prophyBackground data. Controlled, prospective studies that answer this question have not been performed to date. Empirical lactic and empirical therapy conservatively. formed. Background data. The pharmacokinetic properties of antifungal compounds in children differ from those in adults. Lee
Management of Candidemia in Neutropenic Patients
and colleagues [13] investigated the safety, tolerability, and pharmacokinetics of fluconazole in neutropenic children with
As discussed above, the investigators unanimously agreed neoplastic diseases and found that the mean terminal plasma that all candidemic neutropenic patients should be treated with half-life of fluconazole ({SD) was substantially shorter than an antifungal agent. that in adults (i.e., 16.8 { 1.1 hours vs. 27 -37 hours, respectively). The linear dose proportionality to peak plasma concenWhich antifungal agents should be used for trations for children was similar to that for adults. These findmanaging candidemia in stable neutropenic patients?
ings were confirmed by Seay et al. [14] , who found that the mean plasma half-life of fluconazole ({SD) in children with
Background data. Underlying disease, use of indwelling leukemia or other hematologic diseases was 15.6 { 3.2 hours, catheters, severity and duration of the neutropenia, use of antiwhich again is approximately one-half that in adults.
fungal prophylaxis or cytotoxic chemotherapy regimens, and Despite the differences in the pharmacokinetic properties of epidemiology of fungal infections within a given institution amphotericin B in infants, the recommended milligram-perwere considered by the investigators to be critical factors in kilogram dose of amphotericin B for children is similar to that determining how to treat neutropenic patients. Because these for adults; this recommendation has been summarized prefactors differ among institutions, the neutropenic patient popuviously [15] . The renal clearance of 5-fluorocytosine tends to lation is highly heterogeneous. The lack of large-scale, comparbe more rapid in children than in adults; therefore, the dose ative studies of neutropenic patients precludes a simple, unified should be adjusted to achieve near-peak plasma levels of answer to this question. 40-60 mg/mL [16] .
Responses. In the absence of an optimal database, 17 of Responses. In light of the more rapid clearance of flucona-20 investigators chose fluconazole for a stable neutropenic pazole in children, the investigators recommended that life-threattient with uncomplicated candidemia, assuming that triazoles ening invasive candidiasis in children be treated with fluconahad not been administered prophylactically before the onset of zole at a dosage of 6 mg/kg twice daily, assuming that renal candidemia and that there were no sites of hematogenously function is normal. Twice-daily dosing provides an area under seeded infection or other forms of deep candidal infection. The the concentration vs. time curve in children that approximates remaining three investigators chose amphotericin B. Experithat in adults treated once daily. This dosing recommendation mental findings in profoundly neutropenic rabbits may provide for children does not apply to infants, whose renal clearance a scientific foundation for this strategy [25] . The results of of fluconazole is slower than that of older children. For children a study to compare the efficacy of fluconazole with that of with mucosal candidiasis, a fluconazole dose of 2 -3 mg/kg amphotericin B have been published [26] but were not available may be administered once daily [17] . Amphotericin B should at the time of the consensus conference. be used to treat life-threatening invasive candidiasis.
The investigators' selection of fluconazole over amphotericin B was based primarily on fluconazole's relative lack of toxicity. Itraconazole was discussed as an alternative, but it was considHow long is follow-up necessary for both neutropenic ered to have the disadvantages of being unavailable in intraveand nonneutropenic patients who develop nous form and of having variable absorption when given orally candidemia?
to this population of patients. In addition, data from large, convincing studies on the efficacy of itraconazole for candidal The investigators unanimously agreed that because of the late complications of candidemia (such as hematogenous eninfections are lacking at present, and the drug has not been approved for treatment of deep candidal infections by governdophthalmitis; hematogenous osteomyelitis; and chronic disseminated candidiasis of the liver, spleen, or kidneys), all neumental authorities in various countries. The selection of a firstline therapeutic agent for neutropenic patients under a variety tropenic and nonneutropenic patients with candidemia should be routinely followed up for §3 months after the initial episode of clinical circumstances is discussed below. While cost issues / 9c33$$jy25 06-11-97 09:36:32 cida UC: CID were considered, they were thought to be less important in the due to C. glabrata and Candida tropicalis than with infections due to C. albicans and Candida parapsilosis [2] . choice of the first-line agents than were clinical advantages
Responses. Fluconazole therapy is frequently initiated before the Canfor susceptibility testing has not been standardized. Efforts are dida species is identified. In such a circumstance, five of 18 under way to standardize susceptibility testing for fungi by the investigators would continue fluconazole therapy even after C. NCCLS [27] and the European mycological societies. Once glabrata had been identified if a patient was responding to this standardization has been completed, a more meaningful treatment. However, 13 of 18 investigators would change the correlation of in vitro susceptibilities and the in vivo efficacy treatment to amphotericin B once the species was identified as of antifungal agents will be possible. Efforts are also in progress C. glabrata, regardless of the clinical response. If the isolate to develop a correlation between in vitro data and clinical was identified as C. krusei, all of the investigators indicated outcome [28] . The conference participants recommended that they would not use fluconazole. The preferred alternative to until fungal susceptibility testing is fully standardized, fungal fluconazole in each of these clinical situations was a treatment isolates should not be routinely tested for susceptibility to antiregimen that included amphotericin B. fungal agents in the clinical laboratory.
A method used in most institutions to rapidly separate iso-C. albicans clinical isolates, particularly those from patients lates into C. albicans and non-albicans species is the germ who have not received prior treatment with azoles, are usually tube test [31] . Isolates that are germ tube negative are nearly susceptible in vitro to the azoles [29] . However, susceptibility always non-albicans species. As discussed above, non-albicans may vary in patients who have received repeated courses of species vary in their susceptibility to fluconazole [30] . Two azoles. Non-albicans species vary in susceptibility to the days are usually required to definitively identify germ tubeazoles. For example, Candida krusei is intrinsically resistant negative organisms. If germ tube -negative organisms are reto fluconazole, and Candida glabrata may be relatively resiscovered from blood before the species is identified, five of 20 tant to fluconazole [30] .
investigators would continue treatment with fluconazole in all It is of interest that one study showed that statistically sigpatients who were responding to the drug, 13 of 20 would continue treatment with the drug only in patients considered nificantly higher mortality rates are associated with infections / 9c33$$jy25 06-11-97 09:36:32 cida UC: CID The investigators agreed that when 5-fluorocytosine is used, is currently commercially available. A differential culture meespecially in combination with amphotericin B, severe bone dium, CHROMagar Candida (CHROMagar Co., Paris), is marrow depression may occur. This depression is especially available, and published studies indicate that it is reliable for common in neutropenic patients who have received antineothe presumptive identification of C. albicans, C. tropicalis, and plastic chemotherapy [37] and patients who have undergone C. krusei [36] .
bone marrow transplantation. Although the specific dose of 5-fluorocytosine was not discussed, there was general agreement that doses lower than those recommended in the package insert Table 4 shows the responses of the investigators. 41]. However, an in vivo study did not demonstrate this antagoThree chose regimens that did not include amphotericin B nism [44] . This topic has been well reviewed [43] , and a trial because they believed that there are no substantive data demonof amphotericin B plus fluconazole for the treatment of candistrating a high level of efficacy of amphotericin B in this clinidemia in nonneutropenic patients is currently under way under cal situation. These investigators reemphasized that comparathe supervision of investigators at the MSG. tive studies are needed to validate the superiority of any one To treat patients with neutropenia who initially receive amregimen over another.
photericin B and whose conditions become clinically stable or improve (even though neutropenia persists), eight of 20 investigators would change the therapeutic regimen to fluco-
Should the dose of antifungals be increased in
nazole alone, assuming there are no contraindications to the neutropenic patients with candidemia?
use of fluconazole, such as recovery of a resistant isolate. There was no consensus regarding a specific dose or the duration of In part because of a paucity of clinical-trials data, the investigators disagreed on the need for an increased dose of antifuntherapy with amphotericin B before therapy was changed to / 9c33$$jy25 06-11-97 09:36:32 cida UC: CID fluconazole. However, the investigators agreed that a patient Responses. Despite these qualifications, the group unanimously agreed with the recommendations of these two socieshould be clinically stable before therapy is changed. If the neutropenia resolved and the patient remained stable, 17 of 20 ties. This consensus was based on evidence that in addition to accelerating recovery from neutropenia, certain colony-stimuinvestigators would change treatment to that with fluconazole. Itraconazole was discussed as an alternative, but, as mentioned lating factors may enhance the activity of neutrophils against Candida species [50, 51] . above, it has not been approved by governmental agencies in various countries for treatment of deep candidal infections, and there are few data to support its use.
What is the role of prophylactic antifungals in
Although dose-ranging studies for either azoles or amphoterneutropenic patients at high risk for candidal icin B have not been performed in patients with candidemia
infections?
or deep candidal infections, there was general agreement on a dose of 800 mg/d of fluconazole and §0.7 mg/(kgrd) of Background data. Before administering antifungal agents prophylactically, it is important to implement general measures amphotericin B for adults. Some of the investigators would use £1.5 mg/(kgrd) of amphotericin B in unstable patients. The to reduce the possibility that a patient will acquire a disseminated mycosis. Optimal hygiene, including hand washing by dose of 800 mg/d of fluconazole is consistent with that used in the candidemia trial that is being conducted by the MSG visitors, nurses, doctors, and other personnel, is paramount. Neglect of this principle undermines the efficacy of all other and has been supported by the results of a recent study in which 400 mg/d were compared with 800 mg/d in a sequential sophisticated or expensive interventions. For many clinicians concerned about the possibility of lifefashion [10] .
Furthermore, the 800-mg dose was selected because a 15% threatening infections during aggressive treatment of a malignant disease, the temptation to use one of the available antifailure rate was observed in a previous study [4] and because of the lack of toxicity of the 400-mg dose. There was also fungal drugs prophylactically is irresistible. Unfortunately, the efficacy of such a strategy is controversial for most patients. unanimity on continuing treatment for §2 weeks after the last positive blood-culture results are obtained and all clinical maniThe findings of previous studies on the prophylactic use of polyenes and older azoles are generally outdated since the festations of candidal infection have resolved. Antifungal therapy should be continued throughout the duration of neutropenia chemotherapy regimens for hematologic malignancies and solid tumors have changed substantially. Earlier studies of the to prevent relapse of infection.
oral polyenes (nystatin and amphotericin B) and the older imidazoles (miconazole, ketoconazole, and clotrimazole), show that these drugs are active against superficial infections caused by
What is the role of treatment with cytokines in
C. albicans but are largely ineffective in the prevention of neutropenic patients with candidal infections? disseminated mycoses [29, 52, 53] . Two studies have shown a reduction in the incidence of Background data. Members of the American Society of Clinical Oncology recently recommended that granulocyte colhematogenously disseminated deep-organ fungal infection among bone marrow transplant recipients given fluconazole ony-stimulating factor (G-CSF) or granulocyte-macrophage colony-stimulating factor (GM-CSF) be administered to adults prophylaxis [54, 55] . Another study, performed in leukemic patients with neutropenia, showed a reduction in the incidence and children with febrile neutropenia, for whom the expected incidence of infection is §40% [45, 46] . These cytokines are of mucocutaneous candidiasis but not in that of hematogenously disseminated fungal infections [56] . Additional probalso recommended for future chemotherapy cycles after a documented febrile episode occurs in association with neutropenia lems with the use of fluconazole as prophylaxis in leukemic patients and bone marrow transplant recipients include the variduring a prior chemotherapy cycle. Similar recommendations have been made by the European School of Oncology Consenable susceptibilities of non-albicans species and the risk of infection with molds that are resistant to fluconazole. In institusus Conference [47] . These recommendations are designed to prevent future infectious complications and to maintain dose tions where there is a high rate of infection with Aspergillus species, investigators have used ''low-dose'' amphotericin B intensity during subsequent treatment cycles. They also apply to high-dose chemotherapy given to patients undergoing autolin neutropenic bone marrow transplant recipients [57] . However, this strategy remains controversial and numerous prospecogous progenitor cell transplantation.
Recombinant G-CSF or GM-CSF are also recommended for tive controlled studies have not been performed. The use of low-dose amphotericin B in leukemic neutropenic patients also persistently neutropenic patients who have proven invasive candidiasis and are not already receiving a recombinant colonyremains controversial. There are only a few studies of prophylaxis with itraconastimulating factor. These recommendations have been made in the absence of any data from clinical trials, and it is not clear zole. In retrospective uncontrolled studies, Boogaerts et al. [58] and Thunnissen et al. [59] found that the prophylactic use of that the use of cytokines prolongs survival. The issue is discussed further in two reviews [48, 49] .
itraconazole in patients with neutropenia decreased the inci-/ 9c33$$jy25 06-11-97 09:36:32 cida UC: CID dence of fungal infection. A gradual shift in the species of dictive of the development of candidemia. Such findings allow the identification of subsets of patients who would benefit pathogenic fungi was seen, leading to a reduction in C. albicans and Aspergillus infections and an increase in C. glabrata, Fufrom prophylaxis (some investigators would use positive results of surveillance cultures to define a subset of patients at sarium, and Mucorales infections. Vreugdenhil and colleagues [60] observed a lower incidence of C. albicans infections when high risk who are candidates for empirical rather than prophylactic strategies). However, the cost of surveillance cultures itraconazole, rather than placebo, was administered; however, there was no significant improvement in the prevention of funhas limited their routine use in all the centers represented by the investigators at this meeting. This topic has been well gal infections, nor was there a decrease in mortality with itraconazole.
reviewed [67] . Todeschini and colleagues [61] Background data. The rationale for empirical antifungal reported [40] , but more extensive clinical experience and contherapy is to treat invasive fungal infections at the earliest stage trolled trials are needed. Large controlled clinical trials for in patients at high risk for such infections. Empirical therapy evaluating itraconazole as chemoprophylaxis are ongoing. Adwas considered appropriate for neutropenic patients who were ministration of ketoconazole has also been found to diminish at high risk for developing fungal infections, had had persistent colonization with Candida species in susceptible populations, fever for 5 -7 days despite appropriate antibacterial therapy but this drug is not considered effective in preventing dissemin-(some investigators considered 3 days as the criterion), and ated candidiasis [62] .
had no identifiable source of fever after a thorough evaluation Responses regarding prophylaxis in neutropenic leukemic for a nonfungal (i.e., bacterial or viral) infection. Benefit from patients. There was no strong agreement among the investigathe use of amphotericin B therapy in neutropenic patients has tors regarding the use of prophylactic fluconazole, itraconazole, been reported [68] . In a randomized pilot study, investigators or amphotericin B in neutropenic leukemic patients. Until furfound that fluconazole was equivalent to amphotericin B as ther studies are conducted, clinicians at each center will have empirical therapy in persistently febrile and neutropenic cancer to determine their own strategies on the basis of the unique patients at low risk for aspergillosis, as measured by response fungal epidemiology at the center.
of fever and survival [69] .
Responses regarding prophylaxis in bone marrow transplant
Responses. The investigators' responses regarding the use patients. In a prospective, double-blind, placebo-controlled, of empirical therapy in neutropenic patients when a mould multicenter study of patients undergoing bone marrow transinfection appeared either unlikely or likely are summarized in plantation, prophylaxis with fluconazole at a dose of 400 mg figure 5 . When a mould infection was likely, amphotericin B once daily was shown to be effective in preventing superficial was chosen by nearly all the investigators. and disseminated candidiasis and was associated with a lower overall mortality [55] . These results were confirmed in a retro-
Management of Candiduria
spective study in which a lower dose of 100 -200 mg/d was given [63] . The data from a study by Goodman and associates Candiduria is one of the most difficult problems related to [54] , who used a dose of 400 mg/d, are the most convincing.
candidal infections [70] . It is frequently not clear whether the The results from another study suggested that a lower dose of yeast is merely colonizing the bladder or causing infection, fluconazole (e.g., 150 mg/d or 200 mg/d) may suffice in cases of whether the bladder or the kidney is involved if infection is neutropenia [64] . Fluconazole was well tolerated at all dosages.
deemed to be present, or whether the yeast in urine is present Selection of resistant species, such as C. glabrata and C. krusei, as a result of hematogenous dissemination or reflects ascending may be a problem [3] , but such selection did not occur in infection. Despite the many questions that invariably arise in several prospective, randomized studies involving neutropenic the care of patients with candiduria, there was surprising agreepatients [56, 65, 66] . ment among the investigators with regard to treatment. There was strong agreement among the investigators that prophylaxis with fluconazole is effective in patients undergoing A total of 20 investigators, who attended the consensus conference on candidal infections, voted. Considerable discussion was generated by this response. Most of the investigators concluded that mould infection and infection by fluconazole-resistant Candida species are unlikely and that a bacterial or viral infection is the most likely cause of fever in neutropenic patients. Therefore, the investigators would elect to continue fluconazole therapy. The results of a surveillance culture, however, might lead to a different treatment decision.
Their reasons were that colonization is exceedingly common, that all catheters and prosthetic materials should be removed, if possible. that it is often caused by antibiotic and catheter use, and that removing these factors usually leads to clearing of the canWhat is the most appropriate therapy for candidal diduria [70, 71] . B as the treatment of choice. These two treatments have been diduria is warranted in this situation. Their position was based compared in only a few studies, but they seem to be equally on data showing that candidemia can be linked to a urinary efficacious [71, 74] . tract source and often occurs after genitourinary tract manipulation [72] .
What is the most appropriate therapy for presumed upper urinary tract infection due to non-krusei Should prosthetic materials in the urinary tracts of Candida species? patients with candiduria be removed?
Sixteen of 18 investigators preferred initial treatment with It is not surprising that since catheters are a major risk factor fluconazole. One investigator selected itraconazole capsules, and one chose intravenous amphotericin B. for the development of candiduria, all the investigators believed / 9c33$$jy25 06-11-97 09:36:32 cida UC: CID
Management of Selected Candidal Infections of Specific Organs
How should chronic disseminated candidiasis (formerly called hepatosplenic candidiasis) be managed in patients who are no longer neutropenic? How should patients with possible or probable candidal peritonitis be managed?
Background data. Two studies have shown a successful Background data. Since Candida inhabits the healthy gasresponse to fluconazole in patients with chronic disseminated trointestinal tract, there is always a risk that Candida peritonitis candidiasis who have been treated initially with amphotericin will develop following any perforation of the intestines. In B [75, 76] . Furthermore, the progress of treatment can be moniaddition, Candida may be present in the stomach, especially tored with CT scans. If a patient is not responding to azole in situations of relative alkalinity. The management of perforatherapy, alternative agents such as amphotericin B or lipid tion of the gastrointestinal tract remains controversial with reformulations of amphotericin B can be used. spect to antifungal therapy for suspected candidal peritonitis.
Responses 5-fluorocytosine was chosen by all of the investigators. After consultation with an ophthalmologist, the intravitreal adminisMost of the investigators would give antifungal therapy to a patient whose peritoneal culture yields Candida species, even tration of an antifungal can be considered, but this practice is controversial. Partial vitrectomy should also be considered. if bacteria were isolated in association with Candida. In general, positive cultures of peritoneal drains were considered by the investigators to be of less significance than positive cultures Antifungal Therapy in Solid Organ Transplant Recipients of specimens obtained directly from the cavity.
All investigators agreed that prosthetic materials such as The prevention and treatment of candidal infection in solid organ transplant recipients is complicated by the potential for drains should be removed whenever possible from patients with suspected candidal peritonitis.
interactions between antifungal drugs and cyclosporine and contamination with nonabsorbable antifungal agents that are Because of these pharmacologic considerations, the mainadministered before and after the operation. stays of anticandidal therapy in the organ transplant recipient All lung and heart-lung transplant recipients should receive are fluconazole and amphotericin B. At present, liposomal amfluconazole prophylaxis for a minimum of 10 -14 days after photericin B is reserved for patients with renal toxicity who transplantation to protect the bronchial tissue and tracheobronstill require amphotericin B therapy. chial tree, but this recommendation is not based on solid data. In institutions in which aspergillus infections are frequent after lung transplantation, use of antifungals with antiaspergillus acHow should candidemia be managed in the stable tivity should be considered during the first 10 -14 days of the patient after solid organ transplantation?
postoperative period. The rate for visceral seeding following candidemia in solid organ transplant recipients is significantly higher than that for the general population, exceeding 50% at some centers [86] .
How should mucocutaneous candidiasis that develops
Therefore, there was agreement among the investigators that after organ transplantation be managed?
all candidemic organ transplant recipients should be treated with antifungals and that they should receive systemic therapy For the majority of organ transplant recipients with mucocutaneous candidiasis, topical therapy with oral nystatin or clotrifor a minimum of 2 weeks after the last positive blood culture is performed and clinical response has occurred. In addition, mazole for 7 days is usually adequate for eradicating the infection. Topical therapy is recommended to minimize the number all nonessential vascular access lines, including temporary subclavian catheters, should be removed (arteriovenous fistulas of systemic drugs such patients receive. For patients who fail to respond to such therapy, fluconazole at a dose of 200 -400 created for dialysis access are the exception). Initial therapy should be similar to that discussed for stable neutropenic pamg/d is the treatment of choice. Low-dose amphotericin B (5 -10 mg/d administered intravenously for 7 -10 days) is reserved tients. If such a patient has not received fluconazole, then 18 of 18 investigators would recommend initial therapy with flufor the rare patient who fails to respond.
/ 9c33$$jy25 06-11-97 09:36:32 cida UC: CID 
How should asymptomatic candidal colonization of
In general, the investigators participating in this consensus the urinary tract and biliary tree after solid organ conference agreed on the need for a much more aggressive transplantation be managed?
approach to the management of candidal infections with antifungal agents than was the practice in the past, when many Background data. Asymptomatic candiduria that persists candidemic patients were not treated with chemotherapeutic even after removal of the urinary catheter is a common problem agents. This consensus is based on an appreciation for the among renal transplant recipients. Asymptomatic candiduria potentially high morbidity and mortality associated with canoccurs frequently in diabetic patients with poor bladder funcdidal infections and the availability of the newer anticandidal tion and also in renal transplant recipients who are being treated agents, which are less toxic than amphotericin B. There was a with high-dose steroids and have incomplete bladder emptying. strong consensus that all candidemic patients should be treated There is a significant risk of ureterovesical obstruction from a and that intravenous lines should be withdrawn from candifungal ball, of ascending infection, and of candidal pyelonedemic patients whenever feasible. Although there are few studphritis with candidemia. Because of these potential complicaies in which the azoles have been compared with amphotericin tions, preemptive therapy for asymptomatic candiduria is advo-B for nearly all forms of candidal infections, most of the invescated.
tigators would use fluconazole as first-line therapy for stable Responses. Fluconazole was agreed upon as the treatment patients with candidal infections (the other azoles are not apof choice for these infections (unless they were due to proved for treatment of deep candidal infections in the United C. krusei or C. glabrata). If candiduria is due to these moreStates at this time). For patients with life-threatening infections, resistant species, therapy with low-dose amphotericin B, either amphotericin B was generally considered the first-line agent alone or in combination with 5-fluorocytosine, is recomof choice. Amphotericin B was also chosen for treatment of mended.
infections due to isolates of Candida that are highly resistant Candidal colonization of the biliary tree occurs less comto azoles (e.g., C. krusei). monly in the first few months after liver transplantation (at a
The advisability of prophylactic and empirical antifungal time when the T-tube is still in place and biliary specimens therapy is a complex issue, and practices vary considerably for culture can be obtained with ease). Since such colonization from institution to institution. There was strong agreement reof the biliary tree can also result in obstruction that causes garding the benefit of fluconazole prophylaxis in bone marrow ascending cholangitis, treatment of asymptomatic colonization transplant recipients. Because of the development of resistance of this site was also advocated by the investigators. Treatment to the azoles and the lack of solid data indicating their prophyapproaches are the same as those discussed above for the urilactic efficacy, there was concern regarding the widespread use nary tract.
of prophylaxis in other patient populations such as neutropenic leukemic patients and patients hospitalized in surgical intensive Summary care units. Some investigators favored the empirical use of fluconazole in patient populations or hospitals in which the The incidence of candidal infections has increased to the likelihood of mould infections is low. Where mould infection point that Candida is the fourth most common organism isorates are high, the inclusion of amphotericin B -containing lated from the blood of hospitalized patients. The trends associregimens was favored. ated with this increase include a shift in the incidence of species
The introduction of the azoles has provided efficacious, less to more non-albicans isolates and the appearance of candidal toxic agents for treating candidal infections. Additional studies isolates resistant to both amphotericin B and the newer azoles.
are now needed to determine the best treatment strategies for There has not been widespread acceptance of a serodiagnostic the various types of candidal infection, to develop a clearer test to determine which patients with candidemia have infection definition of risk factors, to improve our knowledge of candidal in deep organs. The increase in clinical infections with Candida epidemiology, and to develop improved methods of diagnosis. has occurred at a rate that far exceeds the rate of completion of studies addressing the complex issues of treatment.
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